210 related articles for article (PubMed ID: 30901326)
1. Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myeloma.
Rustad EH; Hultcrantz M; Yellapantula VD; Akhlaghi T; Ho C; Arcila ME; Roshal M; Patel A; Chen D; Devlin SM; Jacobsen A; Huang Y; Miller JE; Papaemmanuil E; Landgren O
PLoS One; 2019; 14(3):e0211600. PubMed ID: 30901326
[TBL] [Abstract][Full Text] [Related]
2. Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma.
Hultcrantz M; Rustad EH; Yellapantula V; Jacob A; Akhlaghi T; Korde N; Mailankody S; Lesokhin AM; Hassoun H; Smith EL; Lahoud OB; Landau HJ; Shah GL; Scordo M; Chung DJ; Giralt S; Papaemmanuil E; Landgren O
Clin Cancer Res; 2022 May; 28(10):2160-2166. PubMed ID: 35553646
[TBL] [Abstract][Full Text] [Related]
3. Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients.
Vij R; Mazumder A; Klinger M; O'Dea D; Paasch J; Martin T; Weng L; Park J; Fiala M; Faham M; Wolf J
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):131-139.e1. PubMed ID: 24629890
[TBL] [Abstract][Full Text] [Related]
4. Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma.
Rustad EH; Misund K; Bernard E; Coward E; Yellapantula VD; Hultcrantz M; Ho C; Kazandjian D; Korde N; Mailankody S; Keats JJ; Akhlaghi T; Viny AD; Mayman DJ; Carroll K; Patel M; Famulare CA; Op Bruinink DH; Hutt K; Jacobsen A; Huang Y; Miller JE; Maura F; Papaemmanuil E; Waage A; Arcila ME; Landgren O
Am J Hematol; 2019 Dec; 94(12):1364-1373. PubMed ID: 31571261
[TBL] [Abstract][Full Text] [Related]
5. Single-Cell RNA Sequencing for the Detection of Clonotypic V(D)J Rearrangements in Multiple Myeloma.
Matera A; Marella A; Maeda A; Da Vià MC; Lazzaroni F; Fabris S; Pioggia S; Porretti L; Colombo F; Torricelli F; Neri A; Taiana E; Fabbiano G; Traini V; Genuardi E; Drandi D; Bolli N; Lionetti M
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555330
[TBL] [Abstract][Full Text] [Related]
6. Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma.
Yao Q; Bai Y; Orfao A; Kumar S; Chim CS
J Mol Diagn; 2020 May; 22(5):679-684. PubMed ID: 32151713
[TBL] [Abstract][Full Text] [Related]
7. Immunoglobulin gene rearrangement in Koreans with multiple myeloma: Clonality assessment and repertoire analysis using next-generation sequencing.
Kim M; Jeon K; Hutt K; Zlotnicki AM; Kim HJ; Lee J; Kim HS; Kang HJ; Lee YK
PLoS One; 2021; 16(6):e0253541. PubMed ID: 34166440
[TBL] [Abstract][Full Text] [Related]
8. Improvement of clonality detection rate in multiple myeloma using fluorescent IgH PCR with different sets of primers.
Welterlin V; Debecker A; Tschieb D; Zanetti C; Lange W; Hénon PR
J Hematother Stem Cell Res; 2000 Dec; 9(6):983-91. PubMed ID: 11177613
[TBL] [Abstract][Full Text] [Related]
9. Ig Gene Clonality Analysis Using Next-Generation Sequencing for Improved Minimal Residual Disease Detection with Significant Prognostic Value in Multiple Myeloma Patients.
Ha J; Lee H; Shin S; Cho H; Chung H; Jang JE; Kim SJ; Cheong JW; Lee ST; Kim JS; Choi JR
J Mol Diagn; 2022 Jan; 24(1):48-56. PubMed ID: 34656761
[TBL] [Abstract][Full Text] [Related]
10. Comparison of ancillary studies in the detection of residual disease in plasma cell myeloma in bone marrow.
Zhao X; Huang Q; Slovak M; Weiss L
Am J Clin Pathol; 2006 Jun; 125(6):895-904. PubMed ID: 16690489
[TBL] [Abstract][Full Text] [Related]
11. Interlaboratory Analytical Validation of a Next-Generation Sequencing Strategy for Clonotypic Assessment and Minimal Residual Disease Monitoring in Multiple Myeloma.
Medina A; Jiménez C; Puig N; Sarasquete ME; Flores-Montero J; García-Álvarez M; Prieto-Conde I; Chillón C; Alcoceba M; González-Calle V; Gutiérrez NC; Jacobsen A; Vigil E; Hutt K; Huang Y; Orfao A; González M; Miller J; García-Sanz R
Arch Pathol Lab Med; 2022 Jul; 146(7):862-871. PubMed ID: 34619755
[TBL] [Abstract][Full Text] [Related]
12. Monitoring minimal residual disease in the bone marrow using next generation sequencing.
Rustad EH; Boyle EM
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101149. PubMed ID: 32139014
[TBL] [Abstract][Full Text] [Related]
13. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry.
Puig N; Sarasquete ME; Balanzategui A; Martínez J; Paiva B; García H; Fumero S; Jiménez C; Alcoceba M; Chillón MC; Sebastián E; Marín L; Montalbán MA; Mateos MV; Oriol A; Palomera L; de la Rubia J; Vidriales MB; Bladé J; Lahuerta JJ; González M; Miguel JF; García-Sanz R
Leukemia; 2014 Feb; 28(2):391-7. PubMed ID: 23860448
[TBL] [Abstract][Full Text] [Related]
14. Characterization of novel, recurrent genomic rearrangements as sensitive MRD targets in childhood B-cell precursor ALL.
Zur Stadt U; Alawi M; Adao M; Indenbirken D; Escherich G; Horstmann MA
Blood Cancer J; 2019 Nov; 9(12):96. PubMed ID: 31784504
[TBL] [Abstract][Full Text] [Related]
15. Myeloma immunoglobulin rearrangement and translocation detection through targeted capture sequencing.
Chow S; Kis O; Mulder DT; Danesh A; Bruce J; Wang TT; Reece D; Bhalis N; Neri P; Sabatini PJ; Keats J; Trudel S; Pugh TJ
Life Sci Alliance; 2023 Jan; 6(1):. PubMed ID: 36328595
[TBL] [Abstract][Full Text] [Related]
16. Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA.
Oberle A; Brandt A; Voigtlaender M; Thiele B; Radloff J; Schulenkorf A; Alawi M; Akyüz N; März M; Ford CT; Krohn-Grimberghe A; Binder M
Haematologica; 2017 Jun; 102(6):1105-1111. PubMed ID: 28183851
[TBL] [Abstract][Full Text] [Related]
17. Improving minimal residual disease detection in precursor B-ALL based on immunoglobulin-kappa and heavy-chain gene rearrangements.
Sutton R; Bahar AY; Kwan E; Giles JE; Venn NC; Tran S; Hackenberg N; Pozza LD; Marshall GM; Haber M; van der Velden VH; Norris MD
Leukemia; 2008 Dec; 22(12):2265-7. PubMed ID: 18496559
[No Abstract] [Full Text] [Related]
18. Comprehensive assessment of potential multiple myeloma immunoglobulin heavy chain V-D-J intraclonal variation using massively parallel pyrosequencing.
Tschumper RC; Asmann YW; Hossain A; Huddleston PM; Wu X; Dispenzieri A; Eckloff BW; Jelinek DF
Oncotarget; 2012 Apr; 3(4):502-13. PubMed ID: 22522905
[TBL] [Abstract][Full Text] [Related]
19. Immunoglobulin genes in multiple myeloma: expressed and non-expressed repertoires, heavy and light chain pairings and somatic mutation patterns in a series of 101 cases.
Hadzidimitriou A; Stamatopoulos K; Belessi C; Lalayianni C; Stavroyianni N; Smilevska T; Hatzi K; Laoutaris N; Anagnostopoulos A; Kollia P; Fassas A
Haematologica; 2006 Jun; 91(6):781-7. PubMed ID: 16769580
[TBL] [Abstract][Full Text] [Related]
20. Quantitation of minimal residual disease in multiple myeloma using an allele-specific real-time PCR assay.
Rasmussen T; Poulsen TS; Honoré L; Johnsen HE
Exp Hematol; 2000 Sep; 28(9):1039-45. PubMed ID: 11008016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
